Ginkgo Bioworks Holdings Inc
NYSE:DNA
Intrinsic Value
Ginkgo Bioworks Holdings, Inc. is a biotech company. [ Read More ]
The intrinsic value of one
DNA
stock under the Base Case scenario is
0.6359
USD.
Compared to the current market price of 0.8649 USD,
Ginkgo Bioworks Holdings Inc
is
Overvalued by 26%.
DNA's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
DNA or that its price is influenced by factors unrelated to fundamentals.
Ginkgo Bioworks Holdings Inc's market capitalization is 1.7B USD.
DNA stock price is 0.8649 USD.
DNA stock (0.6359 USD) is 26% less than its price (0.8649 USD).
DNA. Open DCF Valuation
DNA stock (0.6359 USD) is 26% less than its price (0.8649 USD). Open Relative Valuation
DNA has upside potential of 132% compared to the average analyst price target.
Open Wall St Estimates
DNA's Revenue is forecast to grow at a rate of 19% per year over the next 3 years.
DNA's Revenue has dropped by 47% over the past 12 months.
DNA has negative Operating Income for the last twelve months.
DNA has negative Net Income for the last twelve months.
DNA's ROE (Return on Equity) for the past 12 months is negative and is equal to -63%.
DNA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -60%.
DNA has positive Gross Profit for the last twelve months.
DNA's long-term assets (2B USD) exceed its long-term liabilties (568m USD).
DNA has negative Free Cash Flow for the last twelve months.
DNA has negative three-year average ROE (Return on Equity): -122%. The company is not efficient at transforming stockholders' equity into net income.
DNA has negative three-year average ROIC (Return on Invested Capital): -278%. The company is not efficient at using invested capital to generate operating income.
DNA's short-term assets (1B USD) exceed its short-term liabilties (164m USD).
DNA's D/E (Debt to Equity) is very low and is equal to 0.
DNA's Altman Z-Score is very low and is equal to -1.94.
DNA doesn't generate enough operating income (-576m USD) to safely cover interest payments on its debt (83k USD).
Valuation Backtest
Ginkgo Bioworks Holdings Inc
Run backtest to discover the historical profit from buying and selling
DNA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Ginkgo Bioworks Holdings Inc
Balance Sheet Decomposition
Ginkgo Bioworks Holdings Inc
| Current Assets | 1B |
| Cash & Short-Term Investments | 944.1m |
| Receivables | 31.7m |
| Other Current Assets | 25.9m |
| Non-Current Assets | 663.6m |
| Long-Term Investments | 78.6m |
| PP&E | 395m |
| Intangibles | 132m |
| Other Non-Current Assets | 58.1m |
| Current Liabilities | 163.9m |
| Accounts Payable | 9.3m |
| Accrued Liabilities | 110.1m |
| Other Current Liabilities | 44.5m |
| Non-Current Liabilities | 404.3m |
| Other Non-Current Liabilities | 404.3m |
Earnings Waterfall
Ginkgo Bioworks Holdings Inc
|
Revenue
|
251.5m
USD
|
|
Cost of Revenue
|
-54m
USD
|
|
Gross Profit
|
197.5m
USD
|
|
Operating Expenses
|
-773.5m
USD
|
|
Operating Income
|
-576m
USD
|
|
Other Expenses
|
-316.8m
USD
|
|
Net Income
|
-892.9m
USD
|
Free Cash Flow Analysis
Ginkgo Bioworks Holdings Inc
What is Free Cash Flow?
DNA Profitability Score
Profitability Due Diligence
Ginkgo Bioworks Holdings Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Ginkgo Bioworks Holdings Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
DNA Solvency Score
Solvency Due Diligence
Ginkgo Bioworks Holdings Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Ginkgo Bioworks Holdings Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DNA Price Targets Summary
Ginkgo Bioworks Holdings Inc
According to Wall Street analysts, the average 1-year price target for
DNA
is 2.0094 USD
with a low forecast of 1.111 USD and a high forecast of 3.15 USD.
Ownership
DNA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
DNA Price
Ginkgo Bioworks Holdings Inc
| Average Annual Return | -47.98% |
| Standard Deviation of Annual Returns | 47.86% |
| Max Drawdown | -94% |
| Market Capitalization | 1.7B USD |
| Shares Outstanding | 2 032 400 000 |
| Percentage of Shares Shorted | 19.94% |
DNA News
Last Important Events
Ginkgo Bioworks Holdings Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Ginkgo Bioworks Holdings Inc
Company Profile
Ginkgo Bioworks Holdings Inc
Country
Industry
Market Cap
Dividend Yield
Description
Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 641 full-time employees. The company went IPO on 2021-04-19. The firm's platform is used to program cells on behalf of its customers. Its cell programs are designed to enable biological production of products such as therapeutics, key food ingredients, and chemicals derived from petroleum. The firm's platform is used to design, write, and debug deoxyribonucleic acid (DNA) code in engineered organisms to execute programs for its customers. The Company’s platform comprises of equipment, robotic automation, software, data pipelines and tools, and standard operating procedures for genetic engineering, fermentation, and analytics, a library of proprietary genetic assets and associated performance data; and developers and operators of the foundry and codebase. The company serves industries, including chemicals, agriculture, food, consumer products, and pharmaceuticals.
Contact
IPO
Employees
Officers
The intrinsic value of one
DNA
stock under the Base Case scenario is
0.6359
USD.
Compared to the current market price of 0.8649 USD,
Ginkgo Bioworks Holdings Inc
is
Overvalued by 26%.
You don't have any saved screeners yet
